House Bill 2562
115th Congress(2017-2018)
Making Pharmaceutical Markets More Competitive Act
Introduced
Introduced in House on May 19, 2017
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
2562
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Making Pharmaceutical Markets More Competitive Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs.
The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.
The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.
May 19, 2017
05/26/2017
Referred to the Subcommittee on Health.
05/19/2017
Referred to the House Committee on Energy and Commerce.
05/19/2017
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:36:42 PM